P-139Efficacy of a Sequential Treatment Strategy with GEMOX Followed by FOLFIRI in Advanced Cholangiocarcinoma by Sebbagh, S. et al.
posters
P 139 Efficacy of a Sequential Treatment Strategy with GEMOX
Followed by FOLFIRI in Advanced Cholangiocarcinoma
S. Sebbagh1, J. Roux2, C. Dreyer2, C. Neuzillet3, A. de Gramont4, C. Orbegoso5,
O. Hentic6, P. Hammel7, A. de Gramont8, E. Raymond9, T. André10,
B. Chibaudel11, S. Faivre9
1Beaujon Hospital, Clichy, France
2Saint-Antoine Hospital, Paris, France
3Hôpital Henri-Mondor, Créteil, France
4CHUV, Lausanne, Switzerland
5Marques de Valdecilla University Hospital, Santander, Spain
6Hôpital Beaujon, Clichy, France
7Service de Gastroentérologie, Hôpital Beaujon, Clichy, France
8Oncology Department, Institut Hospitalier Franco-Britannique, Levallois-Perret,
France
9Oncology Unit, Centre Hospitalo-Universitaire Vaudois (CHUV), Lausanne,
Switzerland
10Hopital Saint-Antoine, Paris, France
11Institut Franco-Britannique, Levallois-Perret, France
Introduction: Gemcitabine (GEM)-platinum chemotherapy is validated first-line
strategy for patients with recurrent/advanced cholangiocarcinoma (CK), with
progression-free survival (PFS) of 6-8 months. No standard second-line chemotherapy
after GEM-platinum failure exists and data on survival benefit remain limited.
Methods:We retrospectively reviewed patients with recurrent/advanced CK who
received the GEM-oxaliplatin combination (GEMOX) followed by 5-fluorouracil
combined with irinotecan (FOLFIRI) to evaluate the efficacy of the sequential treatment
strategy. Overall survival (OS) and PFS were calculated by Kaplan-Meier method.
Results: Fifty-two patients were analyzed, 21 (40%) had intrahepatic CK, 14 (27%) had
hilar/extrahepatic CK, and 17 (33%) had gallbladder cancer. Median age was 64 years
(range: 38-79 year). Prior to GEMOX, 49 (94%) and 3 (6%) patients were performance
status (PS) 0-1 and PS 2, respectively; and before FOLFIRI, 14 (27%) patients were PS
2-3. Prior curative-intent resection of the primary tumor was performed in 23 (44.2%)
patients and 12 (23.1%) patients received GEMOX adjuvant chemotherapy. After a
median follow-up of 36.3 months, 47 (90.4%) patients completed the treatment strategy.
First-sequence GEMOX and second-sequence FOLFIRI achieved 4.8 months and 3.2
months median PFS, respectively. The global OS for the sequential chemotherapy was
21.9 months. The sequence of FOLFIRI resulted in a median OS of 8.4 months.
Conclusion: The sequence of GEMOX-FOLFIRI is a potential treatment strategy for
patients with recurrent/advanced CK. However, only a modest impact on OS was
observed. Further studies with novel therapeutic agents to improve survival in CK
patients are required.
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